NL-OMON38601已完成2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia - I5S-MC-EFJE (219-727)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eli Lilly
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •[1] Are men or women *18 years of age and *80 years of age.;[2] Diagnosed with primary HC defined as LDL-C *100 mg/dL (2.6 mmol/L) and TG *450 mg/dL (5.1 mmol/L).
- •o A subset of patients (up to approximately 20%) with an LDL-C *80 mg/dL to <100 mg/dL (*2.1 mmol/L to <2.6 mmol/L) will also be allowed.
- •o Includes at least approximately 20% HeFH patients with probable or definite diagnosis
- •based on clinical criteria or genotype (see Manual of Operations [MOO]) and polygenic
- •(non-familial) HC patients.;[3] Are on a stable diet and stable daily dose of atorvastatin, simvastatin (*40 mg/day),
- •rosuvastatin, pravastatin, lovastatin, fluvastatin, or pitavastatin for at least 6 weeks and further adjustments of statin dose are not deemed clinically indicated by the investigator, or up to
- •approximately 20% of patients with history of statin intolerance (i.e. patients who cannot tolerate any dose of at least 1 statin) who are not on statin treatment for at least 6 weeks, with
- •or without a stable dose of ezetimibe for at least 6 weeks.;[4a] Male patients with partner of childbearing potential: agree to use barrier protection
- •during sexual intercourse during the study and for 3 months following the
- •administration of the last dose of investigational product.;[4b] Female patients, including:
- •1) Women not of childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause.Women with an intact uterus are deemed postmenopausal if they have acessation of menses for at least 1 year, or 6 to 12 months of spontaneous amenorrhea with follicle stimulating hormone >40 mIU/mL (>40 IU/L); not
- •taking hormones or oral contraceptives within 1 year.
- •2) Women of childbearing potential who have a negative urine or serum pregnancy test, are not breast feeding, and agree to use a reliable method of birth control up to at least 3 months following the last dose of study drug, where reliable is defined as birth control that results in a low failure rate (that is, <1% per year) when used consistently and correctly. For example:
- •* Combination oral contraceptive pill
- •* Implantable contraceptives
- •* Injectable contraceptives
- •* Intrauterine device
- •* Intrauterine system * for example, Mirena progestin-releasing coil
- •* Contraceptive patch
- •See MOO for additional information regarding reliable methods of birth control.
- •[5] Have given informed consent to participate in the study.
排除标准
- •[6] Have secondary HC or homozygous familial HC. ;[7] Have had myocardial infarction (MI), unstable angina (UA), percutaneous coronary intervention, coronary artery bypass graft, stroke, or deep vein thrombosis/pulmonary embolism within 3 months of screening, or have planned cardiovascular surgery or percutaneous coronary intervention.;[8] Have symptoms consistent with moderate or severe heart failure or are receiving treatment for symptomatic congestive heart failure (CHF) or known left ventricular ejection fraction (LVEF) <30%.;[9] Uncontrolled hypertension characterized by a systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg.;[10] Have diabetes mellitus (type 1 or 2) that requires or is likely to require any injectable glucose lowering therapy (including insulins) during the course of the study or have hemoglobin A1c (HbA1c) *8.5%.;[11] Have thyroid-stimulating hormone (TSH) levels outside normal reference range for the central laboratory. Patients who are clinically euthyroid and on stable thyroid replacement therapy for at least 2 months prior to screening and who are anticipated to remain on this dose throughout the trial period are acceptable exceptions to this criterion.
研究者
相似试验
未知
2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary HypercholesterolemiaHypercholesterolemiaJPRN-jRCT2080222170Eli Lilly Japan K.K.
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-DKEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-NLEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolPrimary hypercholesterolaemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000622-55-CZEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolPrimary hypercholesterolaemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000622-55-PLEli Lilly and Company528